10x Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent ...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a leading provider of accessible ... issued Final Written Decisions invalidating all claims in 10x Genomics’ 10,697,013 and 10,240,197 patents.

March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent ...

Coupled with the invalidation of 10x Genomics’ 10,155,981 patent ... Chief Executive Officer of Parse Biosciences. "Parse offers a fundamentally differentiated solution that makes single cell ...

March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent ...

SEATTLE — Parse Biosciences, a leading provider of accessible and scalable ... issued Final Written Decisions invalidating all claims in 10x Genomics’ 10,697,013 and 10,240,197 patents. Coupled with ...

Following entry of the injunction, the trial scheduled for March 2025 concerning 10x's remaining patent infringement claims against Parse has been stayed pending those appeals. 10x Genomics is ...

(BUSINESS WIRE )--Parse Biosciences , a leading provider of accessible ... issued Final Written Decisions invalidating all claims in 10x Genomics' 10,697,013 and 10,240,197 patents.